Key Questions: How should injectable Opioid Agonist Treatment programs be administered and shaped? What are the BCCSU's recommendations for this type of addiction treatment?
This guidance document was created to provide an overview of the evidence on injectable Opioid Agonist Treatment (iOAT), potential models of care, recommendations for clinical practice, and operational requirements.
The BC Centre on Substance Use (BCCSU) has released the province’s first-ever guidelines for prescribing of injectable treatments for Opioid Use Disorder. It describes three potential models of care, two established and one emerging. These models include a comprehensive and dedicated supervised iOAT program in which clients can access a full complement of care in one setting; an integrated or embedded supervised iOAT program for clients in a less intensive setting within pre-established services; and an emerging model, which is a pharmacy-based supervised iOAT program, allowing for improved access to care in communities where other, more intensive models may not be appropriate or feasible.
- Executive Summary
- Part 1: Evidence and Implementation of Injectable Opioid Agonist Treatment
- Supervised Injectable Opioid Agonist Treatment
- Models of Care
- Section II: Recommendations for Clinical Practice
- General Considerations
- Patient Population and Eligibility
- Obtaining and Preparing Hydromorphone